Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of GC4419 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 17:05 ET
|
Galera Therapeutics, Inc.
Data demonstrate GC4419 reduced duration, incidence and severity of radiation-induced severe oral mucositis in patients with head and neck cancer Abstract selected for 2018 Best of ASCO program ...
Galera Therapeutics Announces Preclinical Data Demonstrating Potential of GC4419 to Improve Effectiveness of Radiation While Preventing Normal Tissue Toxicity
April 16, 2018 16:30 ET
|
Galera Therapeutics, Inc.
MALVERN, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to...
Galera Therapeutics Announces Dosing of First Patient in Phase 1/2 Pancreatic Cancer Clinical Trial of GC4419
February 28, 2018 07:35 ET
|
Galera Therapeutics, Inc.
MALVERN, Penn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to...
Galera Therapeutics Receives FDA Breakthrough Therapy Designation for GC4419 for the Reduction of Severe Oral Mucositis
February 28, 2018 07:30 ET
|
Galera Therapeutics, Inc.
Designation Based on Positive Results of Phase 2b Trial of GC4419 Severe Oral Mucositis Affects 70 Percent of Head & Neck Cancer Patients Receiving Radiotherapy MALVERN, Pa., Feb. 28, 2018 ...
Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 to be Presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium
January 04, 2018 14:40 ET
|
Galera Therapeutics, Inc.
MALVERN, Pa., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...